This study aimed to describe the profile of patients treated with Glar-100 in terms of age, diabetes duration, HbA1c and FPG levels at baseline, prior anti-diabetes medication, etc. Secondary aims of this study included a description of the insulin titration scheme and change in insulin dosage throughout the study duration, patients achieving HbA1c control after six months of treatment, changes in glycemic parameters and weight at three and six months, in addition to estimating the frequency and severity of adverse events (AEs; notably hypoglycemia). Here, INS is linked to Hypoglycemia.